Patients with relapsed multiple myeloma are resistant to commonly used treatments. Researchers are one step closer to understanding the genetic reason why.

Researchers have figured out how to create a mouse model of a rare but fatal skin cancer, a scientific discovery 10 years in the making.

A study suggests substances touted to improve athletic performance can activate a receptor that accelerates the progression of pre-cancerous lesions to pancreatic cancer in mice.

The approach, studied in mice, overcomes the blood brain barrier and breaks the shield tumors build against the immune response.

Eighty percent of patients with a subset of lymphoma saw their cancers shrink after taking zanubrutinib in a clinical trial.

Ultrasound technology has been repurposed as a technique to treat liver tumors in rats.

Tina Reuben was the first patient in one of the few clinical trials for adrenal cancer and hopes that her involvement can help other patients with the rare disease live longer.

In mice, nanomedicine can remodel the immune microenvironment in lymph node and tumor tissue for long-term remission and lung tumor elimination in this form of metastasized breast cancer.

By raising awareness about the correlation between increased radiation exposure and cardiac events, average doses were reduced without minimizing cancer treatment. 

Findings suggest this method could provide data about tumors sooner than MRIs alone.

The trial advances basic science research on the relationship between purine levels and treatment resistance to develop new treatment options for patients.

Unequal outcomes, and higher spending, seen in patients over 65 who are “dual eligible” for Medicare and Medicaid.

Nearly 2 decades after a groundbreaking discovery, Arul Chinnaiyan wins a prestigious cancer research award.

Often found in beauty products and wellness supplements, hyaluronic acid attracts and retains water well. It’s also a major player in the physiology of pancreatic tumors.

Researchers discover how a gene mutation in the cancerous tumor leads to cell cycle dysregulation and heightened sensitivity to a class of inhibitors.